

# Antenatal screening for haemoglobinopathies in primary care: a cluster randomised trial to inform a simulation model

<b>Submission date</b> 30/04/2004	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
<b>Registration date</b> 30/04/2004	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 31/01/2012	<b>Condition category</b> Haematological Disorders	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Prof Theresa Marteau

### Contact details

King's College London  
5th Floor Thomas Guy House  
Guy's Campus  
London  
United Kingdom  
SE1 9RT  
+44 (0)20 7188 0192  
theresa.marteau@kcl.ac.uk

## Additional identifiers

### Protocol serial number

HTA 03/02/03

## Study information

Scientific Title

**Acronym**

SHIFT (Screening for Haemoglobinopathies In the First Trimester)

**Study objectives**

Offering antenatal screening for sickle cell and thalassaemia when women first report their pregnancy as opposed to offering it as part of community based secondary care increases the proportion of women who know their carrier status before ten weeks gestation.

Protocol can be found at: <http://www.nchta.org/protocols/200300020003.pdf>

More information can be found at: <http://www.hta.ac.uk/1401>

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Ethics approval received from the local medical ethics committee on the 23rd March 2005 (ref: 05/Q0501/36)

**Study design**

Partial factorial cluster randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Screening

**Health condition(s) or problem(s) studied**

Sickle cell and thalassaemia

**Interventions**

Please note that the anticipated end date of this trial has been extended to 30 April 2008 as of 14 December 2007 (Anticipated end date provided at time of registration: 30 September 2007). Closed to recruitment of participants: follow-up continuing.

A partial factorial cluster randomised controlled trial with general practice as the unit of randomisation. Participating general practices will be randomised to offering screening in one of three ways:

Group 1: In primary care, when women first report their pregnancies with parallel partner testing (i.e. partners of all women are offered screening at the same time as the pregnant women)

Group 2: In primary care, when women first report their pregnancies with sequential partner testing; (i.e. partners of women are only offered screening if the pregnant woman is found to be a carrier)

Group 3: In community-based secondary care, when women are booked by midwives with sequential partner testing

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome(s)**

1. Time in pregnancy of offer of carrier screening for sickle cell and thalassaemia
2. Time in pregnancy of testing for carrier status for sickle cell and thalassaemia

**Key secondary outcome(s)**

1. Rates of informed choice about undergoing the screening test
2. Time in pregnancy when women know the carrier status of the babys father
3. Couples emotional responses to carrier testing after they have received their test result

**Completion date**

30/04/2008

**Eligibility****Key inclusion criteria**

1. Eligible pregnant women receiving antenatal care at participating general practices
2. Aged 18 and over
3. Wanting to continue with the pregnancy
4. Carrier status is not documented in primary care records

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

Female

**Key exclusion criteria**

1. Women who do not want to continue with the pregnancies
2. Women who are more than 18 weeks gestation when reporting their pregnancies

**Date of first enrolment**

01/10/2004

**Date of final enrolment**

30/04/2008

**Locations**

## Countries of recruitment

United Kingdom

England

## Study participating centre

King's College London

London

United Kingdom

SE1 9RT

## Sponsor information

### Organisation

Department of Health (UK)

### ROR

<https://ror.org/03sbpja79>

## Funder(s)

### Funder type

Government

### Funder Name

NIHR Health Technology Assessment Programme - HTA (UK)

## Results and Publications

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results published by funding body	01/04/2010		Yes	No
	results published by the BMJ	05/10			

<a href="#">Results article</a>		/2010		Yes	No
<a href="#">Results article</a>	results published by Journal of Medical Screening	01/10/2011		Yes	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes